Finally, although the risk of thromboembolic events is low in patients with breast cancer,1 our findings suggest an elevated risk of VTE in subgroups treated with targeted therapies, especially CDK4/6-inhibitors. This evidence concerns the gene CDK4 and breast carcinoma.